Eli Lilly & Co. (LLY) News

Eli Lilly & Co. (LLY): $770.00

1.12 (-0.15%)

POWR Rating

Component Grades








Filter LLY News Items

LLY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LLY News Highlights

  • LLY's 30 day story count now stands at 26.
  • Over the past 26 days, the trend for LLY's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • AMP, LI and LINK are the most mentioned tickers in articles about LLY.

Latest LLY News From Around the Web

Below are the latest news stories about ELI LILLY & CO that investors may wish to consider to help them evaluate LLY as an investment opportunity.

2024’s Power Players: 7 Stocks Racing to a Trillion Valuation

Whether in 2024, or in the years ahead, each of these seven stocks could become the next trillion dollar companies.

Thomas Niel on InvestorPlace | January 1, 2024

3 Ken Griffin Stocks to Invest Like Citadel

Invest like Citadel founder and billionaire Ken Griffin with these stocks that have strong potential heading into 2024.

Alex Sirois on InvestorPlace | December 30, 2023

Top 3 Large-Cap Growth Stock Picks for the New Year

Crisis is creating opportunity for investors with some of these large-cap growth stocks for New Year 2024.

Ian Cooper on InvestorPlace | December 29, 2023

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Yahoo | December 28, 2023

New weight loss drugs are out of reach for millions of older Americans because Medicare won't pay

New obesity drugs are showing promising results in helping some people shed pounds but the injections will remain out of reach for millions of older Americans because Medicare is forbidden to cover such medications. As obesity rates rise among older adults, some lawmakers say the United States cannot afford to keep a decades-old law that prohibits Medicare from paying for new weight loss drugs, including Wegovy and Zepbound. A look at the debate around if — and how — Medicare should cover obesity drugs: WHAT OBESITY DRUGS ARE ON THE MARKET AND HOW DO THEY WORK?

Yahoo | December 28, 2023

Interested in the Weight-Loss Market? Here's 1 Stock to Buy Hand Over Fist in 2024, and 1 to Avoid Like the Plague.

While Novo Nordisk dominates the weight-loss market, there are two other stocks to consider as well.

Yahoo | December 28, 2023

11 Hot Healthcare Stocks To Buy Now

In this article, we will be taking a look at 11 hot healthcare stocks to buy now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Hot Healthcare Stocks To Buy Now. Healthcare is a vital part of daily living for everyone, whether it be to cure […]

Yahoo | December 28, 2023

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.

Yahoo | December 27, 2023

Lilly Completes Acquisition of POINT Biopharma

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

Yahoo | December 27, 2023

Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.

Things could hardly have gone worse for healthcare investors in 2023. Goldman Sachs analysts called the gap at mid December, with health care stocks down nearly 2% and the S&P 500 up more than 205, the sector’s “most significant annual underperformance in 30 years.” The healthcare sector typically underperforms the broader market in general election years, as presidential hopefuls pledge to reform drug prices or health insurance,  spooking investors into a selloff.

Yahoo | December 27, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!